RT Journal Article
SR Electronic
T1 Procarbazine-induced Genomic Toxicity in Hodgkin Lymphoma Survivors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.04.24308149
DO 10.1101/2024.06.04.24308149
A1 Santarsieri, Anna
A1 Mitchell, Emily
A1 Pham, My H.
A1 Sanghvi, Rashesh
A1 Jablonski, Janina
A1 Lee-Six, Henry
A1 Sturgess, Katherine
A1 Brice, Pauline
A1 Menne, Tobias F.
A1 Osborne, Wendy
A1 Creasey, Thomas
A1 Ardeshna, Kirit M.
A1 Baxter, Joanna
A1 Behan, Sarah
A1 Bhuller, Kaljit
A1 Booth, Stephen
A1 Chavda, Nikesh D.
A1 Collins, Graham P.
A1 Culligan, Dominic J.
A1 Cwynarski, Kate
A1 Davies, Andrew
A1 Downing, Abigail
A1 Dutton, David
A1 Furtado, Michelle
A1 Gallop-Evans, Eve
A1 Hodson, Andrew
A1 Hopkins, David
A1 Hsu, Hannah
A1 Iyengar, Sunil
A1 Jones, Stephen G.
A1 Karanth, Mamatha
A1 Linton, Kim M.
A1 Lomas, Oliver C.
A1 Martinez-Calle, Nicolas
A1 Mathur, Abhinav
A1 McKay, Pamela
A1 Nagumantry, Sateesh K.
A1 Phillips, Elizabeth H.
A1 Phillips, Neil
A1 Rudge, John F.
A1 Shah, Nimish K.
A1 Stafford, Gwyneth
A1 Sternberg, Alex
A1 Trickey, Rachel
A1 Uttenthal, Benjamin J.
A1 Wetherall, Natasha
A1 Zhang, Xiao-Yin
A1 McMillan, Andrew K.
A1 Coleman, Nicholas
A1 Stratton, Michael R.
A1 Laurenti, Elisa
A1 Borchmann, Peter
A1 Borchmann, Sven
A1 Campbell, Peter J.
A1 Rahbari, Raheleh
A1 Follows, George A.
YR 2024
UL http://medrxiv.org/content/early/2024/06/06/2024.06.04.24308149.abstract
AB Background Procarbazine-containing chemotherapy regimens associate with cytopenias and infertility, suggesting stem cell toxicity. Procarbazine in eBEACOPP (escalated dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity, although limited genomic and clinical data support this substitution.Methods To assess mutagenic and clinical consequences of dacarbazine-procarbazine substitutions, we compared mutational landscapes in haematopoietic stem and progenitor cells (HSPCs) from patients treated with different Hodgkin regimens and children, sperm and bowel tissue from procarbazine-treated patients. We compared efficacy and toxicity data of a multicentre eBEACOPDac-treated patient cohort, with eBEACOPP clinical trial and real-world datasets.Results eBEACOPP-treated patients exhibit a higher burden of point mutations, small insertions and deletions in HSPCs compared to eBEACOPDac and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-treated patients. Two novel mutational signatures, SBSA (SBS25-like) and SBSB were identified in HSPCs, neoplastic and normal colon from only procarbazine-treated patients. SBSB was also identified in germline DNA of three children conceived post-eBEACOPP and sperm of an eBEACOPP-treated male. The dacarbazine substitution did not appear to compromise efficacy; 3-year progression-free survival of 312 eBEACOPDac patients (93.3%; CI95=90.3-96.4%) mirrored that of 1945 HD18-trial eBEACOPP patients (93.3%; CI95=92.1-94.4%). eBEACOPDac-treated patients required fewer blood transfusions, demonstrated higher post-chemotherapy sperm concentrations, and experienced earlier resumption of menstrual periods.Conclusions Procarbazine induces a higher mutational burden and novel mutational signatures in eBEACOPP-treated patients and their germline DNA raising concerns for hereditary consequences. However, replacing procarbazine with dacarbazine appears to mitigate gonadal and stem cell toxicity while maintaining comparable clinical efficacy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Addenbrooke's Charitable Trust. The study was funded by the Wellcome Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Health Research Authority of England and Wales gave ethical approval for this work. The Public Benefit and Privacy Panel of Scotland gave ethical approval for this work. The NHS Research Ethics Committee gave ethical approval for this work (REC reference 18/EE/0199, IRAS 149581).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.